alemtuzumab   Click here for help

GtoPdb Ligand ID: 6770

Synonyms: campath 1H | Campath® | campath-1H | Lemtrada®
Approved drug Immunopharmacology Ligand
alemtuzumab is an approved drug (FDA (2001), EMA (2013))
Compound class: Antibody
Comment: CAMPATH-1 (CD52) antigen inhibitor. Functionally, alemtuzumab causes depletion and then recovery of the immune system.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: alemtuzumab

Bioactivity Comments
The necleotide sequences for the CAMPATH-1 antibody were originally identified by Crowe et al. (1992) [1], and this article reports the ADCC effector function of the antibody against K422B lymphoma cells. The reported nucleotide sequences were used to generate an antibody with swapped anti-CAMPATH domains, described in patent US7923538 [4]. The constructed antibodies exhibited improved complement-dependent cytotoxic activity (CDC) and antibody-dependent cell-mediated cytotoxic activity (ADCC) compared to Campath1H-IgG. Affinity data for the interaction between the antibody and the CAMPATH-1 antigen is not provided in either the original article or in patent US7923538 [5].
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
CD52 Primary target of this compound Hs Antibody Binding - - - 2,5
⤷ [2,5]